Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress

– Achieves Third Quarter 2024 Total Revenue of $38.8 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of$29.5 Million; Continued Regulatory and Reimbursement Approvals Globally –– Following FDA Alignment, Absolute Change in Total Symptom Score (Abs-TSS) Will Replace TSS50 as a Co-Primary Endpoint in Phase 3 SENTRY Trial in JAKi Naïve Myelofibrosis (MF); Expected Top-line Data Read-out Remains on Track for 2H 2025 –– Narrows Full-Year 2024 Total Revenue Guidance Range to $145.0 Million to$155.0 Mil ...